SBI Securities Co. Ltd. Invests $115,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

SBI Securities Co. Ltd. purchased a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 32,348 shares of the company’s stock, valued at approximately $115,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. MONECO Advisors LLC purchased a new position in shares of Aquestive Therapeutics during the 4th quarter worth $156,000. New York State Common Retirement Fund boosted its stake in shares of Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares during the last quarter. Harvey Capital Management Inc. boosted its stake in shares of Aquestive Therapeutics by 1,419.3% during the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after acquiring an additional 249,790 shares during the last quarter. Financial Advocates Investment Management boosted its stake in shares of Aquestive Therapeutics by 28.2% during the 4th quarter. Financial Advocates Investment Management now owns 50,000 shares of the company’s stock worth $178,000 after acquiring an additional 11,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Aquestive Therapeutics during the 4th quarter worth $69,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AQST shares. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Finally, Lake Street Capital lowered their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $10.57.

Aquestive Therapeutics Stock Up 2.7 %

Shares of AQST stock opened at $2.65 on Friday. The stock has a market cap of $241.62 million, a P/E ratio of -5.89 and a beta of 2.76. Aquestive Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $6.23. The company’s fifty day simple moving average is $3.09 and its two-hundred day simple moving average is $4.10.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. On average, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.